UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of the treatment of renal cell carcinoma

Author
Michael B Atkins, MD
Section Editor
Jerome P Richie, MD, FACS
Deputy Editor
Michael E Ross, MD

INTRODUCTION

Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma (Wilms' tumor) is common in children (5 to 6 percent of primary renal tumors). (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma" and "Malignancies of the renal pelvis and ureter".)

An overview of the approach to treatment is presented here; more detailed discussions of specific aspects of treatment are discussed in other topics, as noted below.

GENERAL APPROACH

The initial approach to a patient with presumed renal cell carcinoma (RCC) needs to consider the extent of disease, as well as the patient's age and comorbidity (algorithm 1).

RCC can be classified as:

Localized disease – This includes stage IA, IB, II, and III (table 1). (See 'Localized RCC' below.)

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Nov 01 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Santos Arrontes D, Fernández Aceñero MJ, García González JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 2008; 179:857.
  2. Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome. Urology 2004; 64:909.
  3. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.
  4. Volpe A, Panzarella T, Rendon RA, et al. The natural history of incidentally detected small renal masses. Cancer 2004; 100:738.
  5. Rendon RA, Stanietzky N, Panzarella T, et al. The natural history of small renal masses. J Urol 2000; 164:1143.
  6. Wehle MJ, Thiel DD, Petrou SP, et al. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 2004; 64:49.
  7. Rybicki FJ, Shu KM, Cibas ES, et al. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 2003; 180:1281.
  8. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016.
  9. Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med 2016.
  10. Chamie K, Donin NM, Klöpfer P, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol 2016.
  11. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016.
  12. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803.
  13. http://www.ascopost.com/ViewNews.aspx?nid=34072&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4818467.
  14. Atkins MB. Management of advanced renal cancer. Kidney Int 2005; 67:2069.
  15. Flaherty KT, Manola JB, Pins M, et al. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). J Clin Oncol 2015; 33:2384.
  16. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:760.
  17. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32:2765.
  18. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1814.
  19. Vogelzang NJ. Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol 2010; 28:5017.
  20. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303.
  21. Naito S, Eto M, Shinohara N, et al. Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2010; 28:5022.
  22. Mertens WC, Eisenhauer EA, Moore M, et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993; 4:331.
  23. De Mulder PH, Weissbach L, Jakse G, et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37:491.
  24. Casali M, Marcellini M, Casali A, et al. Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study. J Exp Clin Cancer Res 2001; 20:195.
  25. Chung EK, Posadas EM, Kasza K, et al. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2011; 34:150.
  26. Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008; 180:867.
  27. Waters JS, Moss C, Pyle L, et al. Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004; 91:1763.
  28. Stadler WM, Halabi S, Rini B, et al. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006; 107:1273.
  29. Van Veldhuizen PJ, Hussey M, Lara PN Jr, et al. A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312. Am J Clin Oncol 2009; 32:453.
  30. Bellmunt J, Trigo JM, Calvo E, et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11:350.
  31. Kjaer M. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma. Cancer Treat Rev 1988; 15:195.
  32. Oh WK, Manola J, George DJ, et al. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest 2002; 20:186.
  33. Stahl M, Wilke H, Schmoll HJ, et al. A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 1992; 3:167.
  34. Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 2015; 67:740.
  35. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31:181.
  36. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376.
  37. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28:488.
  38. Geynisman DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015; 68:912.
  39. Gollob JA, Upton MP, DeWolf WC, Atkins MB. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058.
  40. Milowsky MI, Rosmarin A, Tickoo SK, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002; 94:111.
  41. Peyromaure M, Thiounn N, Scotté F, et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 2003; 170:1138.
  42. Oudard S, Banu E, Vieillefond A, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol 2007; 177:1698.
  43. Rashid MH, Welsh CT, Bissada NK, Chaudhary UB. Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma. Am J Clin Oncol 2005; 28:107.
  44. Fujiwara Y, Kiura K, Tabata M, et al. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine. Anticancer Drugs 2008; 19:431.
  45. Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 2011; 28:1530.
  46. Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer 2005; 44:407.
  47. Walsh A, Kelly DR, Vaid YN, et al. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer 2010; 55:1217.
  48. Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int 2010; 106:62.
  49. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22:3720.
  50. Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol 2006; 24:e14.
  51. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655.
  52. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966.
  53. Rafla S. Renal cell carcinoma. Natural history and results of treatment. Cancer 1970; 25:26.
  54. Finney R. The value of radiotherapy in the treatment of hypernephroma--a clinical trial. Br J Urol 1973; 45:258.
  55. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13:665.